Blog

A Weighty Dispute: Novo Nordisk’s Semaglutide Patent Clash in Delhi High Court

Introduction A major patent battle [1] has erupted in India between pharmaceutical giants Novo Nordisk and Dr. Reddy’s Laboratories over the popular weight loss and diabetes drug semaglutide. Novo Nordisk sued Dr. Reddy’s for manufacturing and exporting its patented drug without consent. This case is significant for the Indian pharmaceutical industry, as its outcome will […]
Read more

Opinion-Trading Ads: MPL Challenges ASCI White Paper, Seeks $6mil in Damages

Opinion-Trading Ads: MPL Challenges ASCI White Paper, Seeks $6mil in Damages On May 23, 2025, Galactus Funware Technology Pvt Ltd, the parent company of Mobile Premier League (MPL), served an 11-page legal notice to the Advertising Standards Council of India (ASCI). The notice demands two principal remedies: (i) immediate withdrawal of ASCI’s white-paper Examining Opinion Trading […]
Read more

Patentability of Feed Compositions: Madras High Court’s Take on Sections 3(d) & 3(i)

Introduction In KEMIN INDUSTRIES, INC. v. Controller of Patents [1]1, the Madras High Court overturned the rejection of a patent application concerning a method of improving animal feed by supplementing bacterial ferulic acid esterase (FAE) with four specific enzymes. The Patent Office had denied the application under Sections 2(1)(j), 3(d), and 3(i) of the Patents […]
Read more

Deadline Extensions 101 in Indian Patent Law

Introduction On 15th March 2024, the Indian Patent Office (IPO) published the Patent (Amendment) Rules, 2024. Notably, Rules 137 and 138—relating to the Controller’s powers to condone procedural irregularities and extend deadlines were significantly amended. These changes clarify which specific irregularities can now be condoned by the Controller and which deadlines are eligible for extension. […]
Read more

No Patent For Intermediates without Efficacy

Introduction On May 27, 2025, in Zeria Pharmaceutical Co. Ltd. v. Deputy Controller of Patents and Designs1, the Delhi High Court upheld the refusal of divisional patent, affirming that minor structural modifications of known pharmaceutical compounds—especially intermediates—must still demonstrate enhanced therapeutic efficacy to be patentable under Section 3(d) of the Indian Patents Act, 1970. The […]
Read more

India’s Biosimilar Pathway Gets an Update in the Draft 2025 Guidelines

Introduction India’s regulatory landscape for biologic and biosimilar medicines continues to evolve. In response to scientific advances and accumulated regulatory experience, the Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) have jointly released the Draft Guidelines on Similar Biologics – Regulatory Requirements for Marketing Authorization in India, 2025. These proposed guidelines […]
Read more

A Power of Attorney Dispute that Went Too Far

In a significant judgment dated April 22, 2025, the Calcutta High Court (Original Side, Intellectual Property Rights Division) allowed Huawei Technologies Co. Ltd. v. Controller General of Patents, Designs, and Trademarks [1]1, emphatically setting aside a 40-page rejection order passed by the Controller of Patents. The Court held that the application had been rejected not […]
Read more

Supreme Court Clarifies Copyright Vs Design Law

A recent decision by the Supreme Court of India in Cryogas Equipment Pvt. Ltd. v. Inox India Ltd. sheds light on a long standing ambiguity in intellectual property (IP) law: can technical engineering drawings used in manufacturing can be protected under copyright law, or whether they fall under design law instead? Background In 2018, Inox […]
Read more

Subscribe To Our Newsletter

Reach us at knk@kankrishme.com

knk@kankrishme.com
X